Trevi Therapeutics announced the presentation of additional analyses from its Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough (RCC). These results were showcased at an investor meeting during the American Thoracic Society 2025 International Conference.
The additional analyses reinforced the positive topline results announced in March 2025, which showed a statistically significant reduction in objective 24-hour cough frequency. Haduvio achieved a 67% reduction from baseline and a 57% placebo-adjusted reduction (p<0.0001).
Management expressed continued satisfaction with the magnitude and consistency of Haduvio's effect observed in the RIVER trial. The company is awaiting results from its Phase 2b CORAL trial in IPF patients to finalize the development path for both indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.